Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Stock Report

| More

Strides Board approves incremental investments in Stelis

Posted On: 2019-09-20 13:58:02

Strides Pharma Science Limited (Strides or Company) today announced that the Board of Directors of the Company have approved an additional investment up to a maximum of ~US$ 40 million over a period of 24 months for a controlling stake in Stelis Biopharma Private Limited (Stelis).

The proposed new investments will be a primary infusion into Stelis which will enable Stelis to achieve its objective of becoming a compelling global player in the biopharmaceutical space and also accelerate Strides' re-entry into sterile injectables business post the completion of the Company's non-compete period in December 2019.


Stelis was set up to pursue a global biopharmaceutical business with a strategy to develop competitively priced biopharma products and offer high-end CDMO services covering endto-end biopharmaceutical value chain.

As on date, Stelis has invested over ~US$160 million, of which ~US$ 91 million is represented by equity capital infused by Strides and its equity partners. Strides has invested ~US$ 35 million for a ~43% ownership in Stelis. With the aforementioned infusion up to ~US$ 40 million by Strides and pending equity commitments from the other partners, Stelis would have attained a critical size to break even at the operational level which is expected in the next 18 months.


Stelis's business and future growth will thrive on three strategic domains viz. Biopharmaceuticals, CDMO & High-end biologics research services and Sterile injectables.


Stelis's portfolio includes biosimilars produced from microbial production technology. Its portfolio has now attained a reasonable position with significant investments already made into product development and commercial readiness of its compelling biopharma pipeline.

Early Stage Assets

Stelis is building an integrated insulin and insulin analogue platform with proprietary technology. Stelis believes that the platform is one of its kind and has the potential to disrupt the industry paradigm in insulin accessibility and affordability. Stelis's R&D and clinical strategy for insulins are designed for the global markets.

CDMO & High-end biologics research services

CDMO services for drug product and drug substance

Stelis has completed the construction of its modern fully integrated state-of-the-art biopharma manufacturing facility at Bangalore. While the Drug substance block is under installation and validations, the Drug Product block has been validated and now ready for commercial operations. The Drug Product CDMO services have started seeing traction from global players for aseptic fill-finish in various injectable formats and Stelis recently concluded its maiden CDMO contract for fill-finish services with commercial revenues starting from FY20.

Biologics research services

Stelis is now also equipped to offer biologics research services to focus primarily on the development and commercialization of biosimilars, bio betters and New Biological Entities. It has the necessary infrastructure to support microbial and mammalian process developmental activities in therapeutic proteins and monoclonal antibodies both for the early stage and late development which also includes scale-up, preparation of clinical material and stability studies. Stelis is in early discussions with leading global players for offering these services, and the business is expected to commence commercial revenues from FY21.

Sterile Injectables

From December 2019, the envisaged investments will facilitate and accelerate Strides' reentry into sterile injectables domain with a basket of niche products leveraging the group's proven experience and strong capability in the space.

This three-pronged growth strategy is expected to result in meaningful outcomes with Stelis generating operational cash flows to drive its future growth. Stelis is expected to have a positive EPS from FY22 and is well on its course to create significant value in the long-term for all its stakeholder.

Shares of Strides Pharma Science Ltd was last trading in BSE at Rs.359.35 as compared to the previous close of Rs. 366.2. The total number of shares traded during the day was 71010 in over 1085 trades.

The stock hit an intraday high of Rs. 368.35 and intraday low of 355.45. The net turnover during the day was Rs. 25635084.

Source: Equity Bulls

Click here to send ur comments or to

Other Headlines:

Vakrangee announces corporate agency tie up with LIC

Firstsource Solutions Ltd Q4 FY20 consolidated PAT climbs QoQ to Rs. 91.57 crore

Automotive Axles Ltd posts PAT of Rs. 5.75 crore in Q4

Daawat Basmati Rice celebrates relationships with # PehliDaawat Campaign

Newgen Software Technologies Ltd Board approves dividend of Rs. 2 for FY20

Automotive Axles Ltd board recommends dividend of Rs. 0.80

Newgen Software Technologies Ltd Q4 FY20 consolidated PAT up QoQ at Rs. 41.46 crore

McDonald's India Introduces Contactless Take-Out Service For Customers

Infosys and Avaloq Partner to Strengthen Wealth Management Capabilities through Digital Platforms

Reliance Power wins lawsuit in Indonesian Court, to get arbitration award of $68 million

Menon Bearings Ltd Q4 PAT at Rs. 3.30 crore

Indoco receives USFDA approval for Succinylcholine Chloride Injection USP

Steel Strips Wheels Ltd's tractor segment production running at 90% capacity

Orient Electric Ltd board to announce Q4, FY20 results, final dividend on June 1, 2020

Customer Safety in focus: Maruti Suzuki issues safety norms for True Value

Glenmark to commence another new Phase 3 clinical trial on a combination of two anti-viral drugs Favipiravir and Umifenovir in hospitalized patients of moderate COVID-19 in India

Zuari Agro Chemicals Ltd's NPK-A plant resumes operation from May 25, 2020

Polyplex Corporation Ltd Q4 FY2020 consolidated PAT falls to Rs. 22.97 crore

InterGlobe Aviation Ltd board to consider Q4, FY20 results on June 2, 2020

Jubilant Life Sciences Ltd board to approve FY20 results, NCD issue on May 29, 2020

Polyplex Corporation Ltd Board approves final dividend of Rs. 6

IndiGo updates on operations

V-Guard extends support towards fighting Covid-19 crisis

Aptech Ltd reports consolidated loss of Rs. 7.27 crore in Q4 FY20

Music Broadcast Lts has Strong Balance Sheet with cash reserves of Rs. 220 Crores

Bata India Ltd Board recommends Dividend of Rs. 4 for FY20

SpiceJet resumes passenger flight operations

IDFC FIRST Bank Senior Management takes 10% pay cut, MD and CEO takes 30% cut in compensation

Digitate Launches ignio™ AI.Digital Workspace to Transform End-user Workplace Experience

Vindhya Telelinks Ltd board to consider Q4, FY20 results, dividend on June 1, 2020

Dhampur Sugar Mills Ltd board to announce Q4, FY20 results on June 2, 2020

Aarti Industries Ltd Board approves final dividend of Rs. 1 for FY2020

Deepak Fertilisers & Petrochemicals Corporation Ltd Board approves Rights Issue of equity shares

Usha Martin Ltd board to approve Q4, FY2020 results on June 6, 2020

The Federal Bank Ltd board to announce Q4, FY20 results on May 28, 2020

Poly Medicure Ltd Board to consider Final Dividend for FY2020

Wendt India Ltd board to approve Q4, FY20 results, final dividend on May 28, 2020

Jindal Steel & Power Ltd Q4 consolidated PAT at Rs. 406.21 crore

Aarti Industries Ltd posts Rs. 110.35 crore in Q4 FY2020

Just Dial Ltd Q4 FY2020 consolidated PAT at Rs. 76.07 crore

BATA India Ltd reports consolidated Q4 FY20 PAT slumps to Rs. 38.40 crore

Astral Poly Technik Ltd reports lower Q4 FY20 consolidated PAT of Rs. 51.1 crore

Super Sales India Ltd Q4 FY20 net profit at Rs. 0.16 crore

Lakshmi Machine Works Ltd posts Rs. 1.88 crore consolidated net profit in Q4 FY20

Alembic Ltd reports consolidated PAT of Rs. 115.43 crore in Q4 FY2020

HIL Ltd Q4 FY20 consolidated net profit at Rs. 23.76 crore

HDFC Q4 FY20 consolidated PAT at Rs. 4115.20 crore

India Ratings Revises Snowman Logistics' Rating Watch to Evolving

Super Sales India Ltd Board approves dividend of Rs. 2.50

Alembic Ltd Board recommends Dividend of Rs. 0.60

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019